CD147 silencing inhibits tumor growth by suppressing glucose transport in melanoma

Oncotarget

Volumn 7, Issue 40, 2016, Pages 64778-64784

  Su, Juan ^a   Gao, Tianyuan ^a,b   Jiang, Minghao ^a   Wu, Lisha ^a   Zeng, Weiqi ^a   Zhao, Shuang ^a   Peng, Cong ^a   Chen, Xiang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

CD147; GLUT 1; Glycolysis; Melanoma; PI3K Akt pathway

Indexed keywords

CD147 ANTIGEN; GLUCOSE TRANSPORTER 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; EXCITATORY AMINO ACID TRANSPORTER 2; GLUCOSE;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER INHIBITION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; ENZYME LOCALIZATION; GENE SILENCING; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; IMMUNOPRECIPITATION; IN VIVO STUDY; LUNG METASTASIS; MELANOMA; METASTATIC MELANOMA; NONHUMAN; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; CARCINOGENESIS; CELL PROLIFERATION; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; NEVUS; NUDE MOUSE; PROTEIN TRANSPORT; TUMOR CELL LINE;

ANIMALS; BASIGIN; CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; EXCITATORY AMINO ACID TRANSPORTER 2; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE; HUMANS; MELANOMA; MICE; MICE, NUDE; NEVUS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN TRANSPORT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84994175632     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11415     Document Type: Article

References (25)

1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115-32.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7-30.
3. Kamath S, Miller KA, Cockburn MG. Current Data on Risk Factor Estimates Does Not Explain the Difference in Rates of Melanoma between Hispanics and Non-Hispanic Whites. J Skin Cancer. 2016;2016:2105250.
4. Yu L, Chen X, Wang L, Chen S. The sweet trap in tumors: aerobic glycolysis and potential targets for therapy. Oncotarget. 2016; doi: 10.18632/oncotarget.7676.
5. Deng D, Yan N. GLUT, SGLT, and SWEET: Structural and mechanistic investigations of the glucose transporters. Protein Sci. 2016;25:546-58.
6. Parente P, Coli A, Massi G, Mangoni A, Fabrizi MM, Bigotti G. Immunohistochemical expression of the glucose transporters Glut-1 and Glut-3 in human malignant melanomas and benign melanocytic lesions. J Exp Clin Cancer Res. 2008;27:34.
7. Long T, Su J, Tang W, Luo Z, Liu S, Liu Z, Zhou H, Qi M, Zeng W, Zhang J, Chen X. A novel interaction between calcium-modulating cyclophilin ligand and Basigin regulates calcium signaling and matrix metalloproteinase activities in human melanoma cells. Cancer Letters. 2013;339:93-101.
8. Gandini S, Montella M, Ayala F, Benedetto L, Rossi CR, Vecchiato A, Corradin MT, V DEG, Queirolo P, Zannetti G, Giudice G, Borroni G, Forcignano R, et al. Sun exposure and melanoma prognostic factors. Oncol Lett. 2016;11:2706-2714.
9. Hao M, Song F, Du X, Wang G, Yang Y, Chen K, Yang J. Advances in targeted therapy for unresectable melanoma: new drugs and combinations. Cancer Letters. 2015;359:1-8.
10. Chen J, Shao R, Zhang XD, Chen C. Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics. Int J Nanomedicine. 2013;8:2677-88.
11. Fawaz B, Dickson L, Menter A. Pustular psoriasis eruption with dabrafenib, a BRAF inhibitor. J Dermatolog Treat. 2016:1-4.
12. Jonas O, Oudin MJ, Kosciuk T, Whitman M, Gertler FB, Cima MJ, Flaherty KT, Langer R. Parallel in-vivo assessment of drug phenotypes at various time points during systemic BRAF inhibition reveals tumor adaptation and altered treatment vulnerabilities. Clin Cancer Res. 2016.
13. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029-33.
14. Hasanpourghadi M, Looi CY, Pandurangan AK, Sethi G, Wong WF, Mustafa MR. Phytometabolites Targeting Warburg Effect in Cancer Cells: A Mechanistic Review. Curr Drug Targets. 2016.
15. Abdou AG, Eldien MM, Elsakka D. GLUT-1 Expression in Cutaneous Basal and Squamous Cell Carcinomas. Int J Surg Pathol. 2015;23:447-53.
16. Gunnink LK, Alabi OD, Kuiper BD, Gunnink SM, Schuiteman SJ, Strohbehn LE, Hamilton KE, Wrobel KE, Louters LL. Curcumin directly inhibits the transport activity of GLUT1. Biochimie. 2016;125:179-85. doi: 10.1016/j. biochi.2016.03.014.
17. 117 sensitizes radioresistant breast cancer cells to irradiation. Cancer Chemother Pharmacol. 2016;77:963-72.
18. Venturelli L, Nappini S, Bulfoni M, Gianfranceschi G, Dal Zilio S, Coceano G, Del Ben F, Turetta M, Scoles G, Vaccari L, Cesselli D, Cojoc D. Glucose is a key driver for GLUT1-mediated nanoparticles internalization in breast cancer cells. Sci Rep. 2016;6:21629.
19. Fan JY, Yang Y, Xie JY, Lu YL, Shi K, Huang YQ. MicroRNA-144 mediates metabolic shift in ovarian cancer cells by directly targeting Glut1. Tumour Biol. 2016;37:6855-60.
20. Stewart PA, Parapatics K, Welsh EA, Muller AC, Cao H, Fang B, Koomen JM, Eschrich SA, Bennett KL, Haura EB. A Pilot Proteogenomic Study with Data Integration Identifies MCT1 and GLUT1 as Prognostic Markers in Lung Adenocarcinoma. PLoS One. 2015;10:e0142162.
21. Fu ZG, Wang L, Cui HY, Peng JL, Wang SJ, Geng JJ, Liu JD, Feng F, Song F, Li L, Zhu P, Jiang JL, Chen ZN. A novel small-molecule compound targeting CD147 inhibits the motility and invasion of hepatocellular carcinoma cells. Oncotarget. 2016;7:9429-47. doi:10.18632/oncotarget.6990.
22. Liu H, Xu XF, Zhao Y, Tang MC, Zhou YQ, Gao FH. NS398 promotes pancreatic cancer cell invasion by CD147 and MMP2 via the activation of P38. Mol Med Rep. 2016;13:2208-14.
23. Cui HY, Wang SJ, Miao JY, Fu ZG, Feng F, Wu J, Yang XM, Chen ZN, Jiang JL. CD147 regulates cancer migration via direct interaction with Annexin A2 and DOCK3-betacatenin-WAVE2 signaling. Oncotarget. 2016;7:5613-29. doi:10.18632/oncotarget.6723.
24. Dai L, Trillo-Tinoco J, Chen Y, BonstaffK, Del Valle L, Parsons C, Ochoa AC, Zabaleta J, Toole BP, Qin Z. CD147 and downstream ADAMTSs promote the tumorigenicity of Kaposi's sarcoma-associated herpesvirus infected endothelial cells. Oncotarget. 2016;7:3806-18. doi:10.18632/oncotarget.6584.
25. Cohen-Solal KA, Boregowda RK, Lasfar A. RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression. Mol Cancer. 2015;14:137.